Announced Wed, 17 Jun · 12:35 IST
Positive Phase-2b results for Ropanicant in depression trial
Compliance View source PDF
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.9%1-day move
₹270.00
prior close
₹268.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.2-3.5-2.5-1.7-3.9-0.9-2.5-4.3-5.6+3.5+29.6+20.1——
Up moveDown movePending
AI summary
Suven Life Sciences announced positive Phase-2b trial results for Ropanicant, its drug for Major Depressive Disorder. In a 214-patient US trial, Ropanicant 45mg twice daily showed a meaningful reduction in depression scores versus placebo at Week 6 (mean difference -3.57, p=0.038). The drug was well tolerated with no withdrawal symptoms or dissociation. Global Phase-3 study is being planned. Suven owns all IP rights for Ropanicant.
Likely market impact
Positive trial outcome strengthens Ropanicant's development prospects; likely to lift sentiment. Phase-3 plans next key catalyst.